Burkitt lymphoma in the modern era: Real-world outcomes and prognostication across 30 US cancer centers

We examined adults with untreated Burkitt lymphoma (BL) from 2009 to 2018 across 30 US cancer centers. Factors associated with progression-free survival (PFS) and overall survival (OS) were evaluated in univariate and multivariate Cox models. Among 641 BL patients, baseline features included the following: median age, 47 years; HIV1, 22%; Eastern Cooperative Oncology Group (ECOG) performance status (PS) 2 to 4, 23%; >1 extranodal site, 43%; advanced stage, 78%; and central nervous system (CNS) involvement, 19%. Treatment-related mortality was 10%, with most common causes being sepsis, gastrointestinal bleed/perforation, and respiratory failure.With 45-monthmedian follow-up, 3-year PFS andOS rates were 64% and 70%, respectively, without differences by HIV status. Survival was better for patients who received rituximab vs not (3-year PFS, 67% vs 38%; OS, 72% vs 44%; P < .001) and without difference based on setting of administration (ie, inpatient vs outpatient).Outcomeswere also improved at an academic vs community cancer center (3-year PFS, 67% vs 46%, P = .006; OS, 72% vs 53%, P = .01). In multivariate models, age 40 years (PFS, hazard ratio [HR] 5 1.70, P = .001; OS, HR 5 2.09, P < .001), ECOG PS 2 to 4 (PFS, HR 5 1.60, P < .001; OS, HR 5 1.74, P = .003), lactate dehydrogenase > 33 normal (PFS, HR 5 1.83, P < .001; OS, HR 5 1.63, P = .009), and CNS involvement (PFS, HR5 1.52, P5 .017;OS, HR5 1.67, P5 .014) predicted inferior survival. Furthermore, survival varied based on number of factors present (0, 1, 2 to 4 factors) yielding 3-year PFS rates of 91%, 73%, and 50%, respectively; and 3-year OS rates of 95%, 77%, and 56%, respectively. Collectively, outcomes for adult BL in this real-world analysis appeared more modest compared with results of clinical trials and smaller series. In addition, clinical prognostic factors at diagnosis identified patients with divergent survival rates.